JP2005524670A - 放出制御投与形態 - Google Patents

放出制御投与形態 Download PDF

Info

Publication number
JP2005524670A
JP2005524670A JP2003574168A JP2003574168A JP2005524670A JP 2005524670 A JP2005524670 A JP 2005524670A JP 2003574168 A JP2003574168 A JP 2003574168A JP 2003574168 A JP2003574168 A JP 2003574168A JP 2005524670 A JP2005524670 A JP 2005524670A
Authority
JP
Japan
Prior art keywords
dosage form
core tablet
pharmaceutical dosage
pharmaceutical
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003574168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005524670A5 (enExample
Inventor
レルナー，イー．イツハーク
ローゼンベルガー，ベレド
アクア，オフェル
フラシュナー−バラク，モシュ
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2005524670A publication Critical patent/JP2005524670A/ja
Publication of JP2005524670A5 publication Critical patent/JP2005524670A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B30—PRESSES
    • B30B—PRESSES IN GENERAL
    • B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/34—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses for coating articles, e.g. tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003574168A 2002-03-04 2003-03-03 放出制御投与形態 Pending JP2005524670A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36182102P 2002-03-04 2002-03-04
US29161902A 2002-11-12 2002-11-12
PCT/US2003/006591 WO2003075893A1 (en) 2002-03-04 2003-03-03 Controlled release dosage forms

Publications (2)

Publication Number Publication Date
JP2005524670A true JP2005524670A (ja) 2005-08-18
JP2005524670A5 JP2005524670A5 (enExample) 2006-04-13

Family

ID=27807664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003574168A Pending JP2005524670A (ja) 2002-03-04 2003-03-03 放出制御投与形態

Country Status (13)

Country Link
EP (1) EP1492508A4 (enExample)
JP (1) JP2005524670A (enExample)
KR (1) KR20100049695A (enExample)
CN (1) CN1649569B (enExample)
AU (2) AU2003217909C1 (enExample)
BR (1) BR0308305A (enExample)
CA (1) CA2477701A1 (enExample)
EA (1) EA005866B1 (enExample)
IL (1) IL163887A0 (enExample)
MX (1) MXPA04008536A (enExample)
NO (1) NO20044188L (enExample)
NZ (1) NZ535083A (enExample)
WO (1) WO2003075893A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020507556A (ja) * 2016-02-17 2020-03-12 トリアステック インコーポレイテッド 剤形およびそれらの使用
WO2024127880A1 (ja) * 2022-12-12 2024-06-20 パナソニックＩｐマネジメント株式会社 水処理用徐放性固形薬剤

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
RU2005104827A (ru) * 2002-07-19 2006-07-27 Рэнбакси Лабораториз Лимитед (In) Таблетки суматриптана с замаскированным вкусом и способы их получения
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US20040122065A1 (en) * 2002-11-12 2004-06-24 Lerner E. Itzhak Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or buccally
EP1698448B1 (en) * 2003-11-14 2017-01-18 Sanwa Kagaku Kenkyusho Co., Ltd. Method of manufacturing nucleated molding
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
CN1921866A (zh) * 2004-02-19 2007-02-28 特瓦制药工业有限公司 使用雷洛昔芬和阿伦膦酸盐的改善的联合治疗
KR100701409B1 (ko) 2004-11-26 2007-03-30 한국유나이티드제약 주식회사 호박산 수마트립탄을 함유하는 약제학적 조성물
ES2740360T3 (es) 2008-08-15 2020-02-05 Assertio Therapeutics Inc Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC
CN103948556A (zh) * 2014-04-08 2014-07-30 闻晓光 一种新型控释片
CN110604724A (zh) * 2019-10-22 2019-12-24 恒诚制药集团淮南有限公司 一种肠溶美沙拉秦缓释片剂及其制备方法
PE20251521A1 (es) 2022-10-13 2025-06-05 Clarke Mosquito Control Products Inc Composiciones de tabletas insecticidas

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61243016A (ja) * 1985-04-19 1986-10-29 Katsumi Takada 柱状の有効成分含有部分をもつ錠剤
JPS6253918A (ja) * 1985-09-02 1987-03-09 Katsumi Takada 柱状の有効成分含有部分を埋没させた錠剤
JPH08333259A (ja) * 1995-04-03 1996-12-17 Chugai Pharmaceut Co Ltd スクラルファート含有製剤組成物
JPH09110682A (ja) * 1995-09-12 1997-04-28 Bristol Myers Squibb Co 治療薬のバッカル放出性製剤
JPH11199496A (ja) * 1997-12-19 1999-07-27 Merck Patent Gmbh 多層性錠剤
JPH11509829A (ja) * 1994-12-22 1999-08-31 メルク エンド カンパニー インコーポレーテッド 制御放出薬剤懸濁液の送出デバイス
JP2001163769A (ja) * 1999-03-25 2001-06-19 Otsuka Pharmaceut Co Ltd シロスタゾール製剤
WO2001089679A2 (en) * 2000-05-22 2001-11-29 Warner-Lambert Company Continuous production of pharmaceutical granulates
JP2001526227A (ja) * 1997-12-22 2001-12-18 シェーリング コーポレイション バイオアベイラビリティーを高めた分子分散組成物
WO2002000212A1 (en) * 2000-06-28 2002-01-03 Nitrosystems, Inc. Controlled release arginine formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB972128A (en) * 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
GB8514666D0 (en) * 1985-06-11 1985-07-10 Coopers Animal Health Agent delivery systems
DE4431653C2 (de) * 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
EA006053B1 (ru) * 2001-12-24 2005-08-25 Тева Фармасьютикал Индастриес Лтд. Твёрдая лекарственная форма, способ её изготовления и устройство

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61243016A (ja) * 1985-04-19 1986-10-29 Katsumi Takada 柱状の有効成分含有部分をもつ錠剤
JPS6253918A (ja) * 1985-09-02 1987-03-09 Katsumi Takada 柱状の有効成分含有部分を埋没させた錠剤
JPH11509829A (ja) * 1994-12-22 1999-08-31 メルク エンド カンパニー インコーポレーテッド 制御放出薬剤懸濁液の送出デバイス
JPH08333259A (ja) * 1995-04-03 1996-12-17 Chugai Pharmaceut Co Ltd スクラルファート含有製剤組成物
JPH09110682A (ja) * 1995-09-12 1997-04-28 Bristol Myers Squibb Co 治療薬のバッカル放出性製剤
JPH11199496A (ja) * 1997-12-19 1999-07-27 Merck Patent Gmbh 多層性錠剤
JP2001526227A (ja) * 1997-12-22 2001-12-18 シェーリング コーポレイション バイオアベイラビリティーを高めた分子分散組成物
JP2001163769A (ja) * 1999-03-25 2001-06-19 Otsuka Pharmaceut Co Ltd シロスタゾール製剤
WO2001089679A2 (en) * 2000-05-22 2001-11-29 Warner-Lambert Company Continuous production of pharmaceutical granulates
JP2004501679A (ja) * 2000-05-22 2004-01-22 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 医薬顆粒の連続製造
WO2002000212A1 (en) * 2000-06-28 2002-01-03 Nitrosystems, Inc. Controlled release arginine formulations
JP2004513877A (ja) * 2000-06-28 2004-05-13 アンジオジェニックス，アイエヌシー． 放出制御アルギニン製剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020507556A (ja) * 2016-02-17 2020-03-12 トリアステック インコーポレイテッド 剤形およびそれらの使用
WO2024127880A1 (ja) * 2022-12-12 2024-06-20 パナソニックＩｐマネジメント株式会社 水処理用徐放性固形薬剤

Also Published As

Publication number Publication date
IL163887A0 (en) 2005-12-18
WO2003075893A1 (en) 2003-09-18
AU2003217909A1 (en) 2003-09-22
NZ535083A (en) 2007-06-29
MXPA04008536A (es) 2005-09-08
AU2003217909B2 (en) 2008-10-30
AU2009200353A1 (en) 2009-02-19
EP1492508A4 (en) 2009-05-06
BR0308305A (pt) 2004-12-28
CN1649569B (zh) 2010-05-05
CA2477701A1 (en) 2003-09-18
NO20044188L (no) 2004-12-03
AU2003217909C1 (en) 2009-06-11
EA005866B1 (ru) 2005-06-30
KR20100049695A (ko) 2010-05-12
CN1649569A (zh) 2005-08-03
EA200401097A1 (ru) 2005-04-28
EP1492508A1 (en) 2005-01-05

Similar Documents

Publication Publication Date Title
US20040052843A1 (en) Controlled release dosage forms
JP4414228B2 (ja) 活性成分の芯錠剤が粉末または顆粒状材料の圧縮環状体の鞘に収められた剤形とその製造方法および器具類
AU2009200353A1 (en) Controlled release dosage forms
CA2720108C (en) Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US6399100B1 (en) Controlled release pharmaceutical compositions containing tiagabine
KR20070036797A (ko) 장용 코팅된 중심정을 갖는 제형
US20100092557A1 (en) Dosage Form Comprising Immediate Release Naproxen and Sustained Release Opioid Analgesic
KR20050023235A (ko) 방출 조절 투여 형태
AU2002352613B2 (en) Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
ZA200407023B (en) Controlled release dosage forms
US20050032876A1 (en) Pharmaceutical compositions comprising sumatriptan and metoclopramide, and methods of use thereof
JP2008507587A (ja) 腸溶性被覆されたコアー錠剤を有する投与形
ZA200405012B (en) Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of power or granular material, and process and tooling for producing it.

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100622